JPMorgan Downgrades Biogen (BIIB) to Neutral

March 21, 2019 10:29 AM

JPMorgan analyst Cory Kasimov downgraded Biogen (NASDAQ: BIIB) from Overweight to Neutral with a price target of $244.00 (from $436.00).

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $320.59 yesterday.



Next Articles